Investigation of galectin-3 and heparanase in endometrioid and serous carcinomas of the endometrium and correlation with known predictors of survival
- 220 Downloads
Inhibitors of tumor angiogenesis and metastasis are emerging as important new drug candidates for cancer therapy. Galectin-3 and heparanase have been shown to function in tumor progression and metastatic spread. Both of them exert pleiotropic effects; proliferation, cell migration, differentiation and tissue remodeling. The aim of this study was to investigate heparanase and galectin-3 expression in endometrioid and serous carcinomas of the endometrium and their relation with well-known prognostic factors, in addition to estrogen, progesterone, C-erbB-2, Ki-67 and p53.
Materials and methods
Sixty-four endometrial cancers, which include 24 serous types, were obtained from previously untreated patients. Immunohistochemical analysis of 64 carcinomas, 20 endometrial hyperplasia (ten of simple hyperplasia and ten of complex atypic hyperplasia) and 20 normal endometrium (ten of proliferative and ten of secretory) was performed.
This investigation suggests that the decreased expression of galectin-3 may be involved in the pathogenesis of endometrial carcinomas from normal endometrium to carcinoma. Also down-regulated stromal expression of galectin-3 in endometrial carcinoma may be involved in lymph node metastasis. Further studies on a larger advanced stage (FIGO stage 3–4) endometrial carcinoma group may determine the value of heparanase in the endometrial carcinoma.
KeywordsGalectin-3 Heparanase Serous endometrial carcinoma Endometrial hyperplasia
This work is supported by grant of ‘BAP’ comission of Pamukkale University, No 2008TPF009. Some of the findings about galectin-3 were presented orally in the 22nd European Pathology Congress and also this presentation was supported in part by grant of ‘BAP’ comission of Pamukkale University, No 2009KKP073 and 2007KRM001. We thank Dr. Mehmet Zencir and Dr. Özgür Önal for their contributions in statistical analysis and Mr. Emin Ateş for technical assistance.
Conflict of interest
- 3.Ronnett BM, Zaino RJ, Ellenson LH, Kurman JR (2002) Endometrial carcinoma. In: Kurman RJ (ed) Blaustein’s pathology of female genital tract, 5th edn. Springer Verlag, Berlin, pp 501–559Google Scholar
- 4.International Federation of Gynecology and Obstetrics: Annual report on the results of treatment in gynecologic cancer: FIGO. Stockholm, Sweden, International Federation of Gynecology and Obstetrics, 1985Google Scholar
- 8.Dangue A, Camby I, Kiss R (2002) Galectins and cancer. Biochim Biophys Acta 1572:285–293Google Scholar
- 14.Cotter F (2008) Interim phase 2 results on prospect therapeutics’ GCS-100 presented at the 10th international conference on malignant lymphoma. http://www.drugs.com/clinical_trials/interim-phase-2-results-prospect-therapeutics-gcs-100-presented-10th-international-conference-4646.html. Accessed 13 April 2009
- 15.Grous JJ, Redfern CH, Mahadevan D, Schindler J (2006) GCS-100, a galectin-3 antagonist, in refractory solid tumors: a phase I study. ASCO Annual Meeting Proceedings http://www.asco.org/ASCO/Abstracts+&+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=40&abstractID=33305. Accessed 22 March 2009
- 16.Nakajima M, Irimura T, Nicolson GL (1998) Heparanases and tumor metastasis. J Cell Biochem 36:1–11Google Scholar
- 18.Kodama J, Shinyo Y, Hasengaowa, Kusumoto T, Seki N, Nakamura K, Hongo A, Hiramatsu Y (2005) Loss of basement membrane heparan sulfate expression is associated with pelvic lymph node metastasis in invasive cervical cancer. Oncol Rep 14(1):89–92Google Scholar
- 20.Parish CR, Freeman C, Brown KJ, Francis DJ, Cowden WB (1999) Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res 59:344–3433Google Scholar
- 21.Vlodavsky I, Mohsen M, Lider O, Svahn CM, Ekre HP, Vigoda M et al (1994–1995) Inhibition of tumor metastasis by heparanase inhibiting species of heparin. Invasion Metastasis 14:290–302Google Scholar
- 59.Hasengaowa, Kodama J, Kusumoto T, Seki N, Matsuo T, Ojima Y et al (2006) Heparanase expression in both normal endometrium and endometrial cancer. Int J Gynecol Cancer 16(3):1401–1406Google Scholar
- 61.Xu X, Rao G, Quiros RM, Kim AW, Miao HQ, Brunn GJ, Platt JL, Gattuso P, Prinz RA (2007) In vivo and in vitro degradation of heparan sulfate (HS) proteoglycans by HPR1 in pancreatic adenocarcinomas. Loss of cell surface HS suppresses fibroblast growth factor 2-mediated cell signaling and proliferation. J Biol Chem 282:2363–2373PubMedCrossRefGoogle Scholar